38 results match your criteria: "Antwerp University and University Hospital[Affiliation]"
Is it the right time to promote competency-based European Training Requirements in Ophthalmology? A European Board of Ophthalmology survey.
Acta Ophthalmol
December 2024
Department of Ophthalmology, New Civil Hospital, Strasbourg University Hospital, FMTS, Strasbourg, France.
Purpose: To report national practices and recent progress in competency-based medical education (CBME) implementation in ophthalmology across European countries.
Methods: A 30-question online survey was emailed to European Union of Medical Specialists (UEMS) ophthalmology section delegates, European Board of Ophthalmology Diploma (EBOD) examiners and presidents of ophthalmology societies affiliated with UEMS/EBO.
Results: A total of 230 ophthalmologists with an average age of 54.
Reply: Cataract surgical training in Europe: European Board of Ophthalmology survey.
J Cataract Refract Surg
August 2024
From the Department of Ophthalmology, Strasbourg University Hospital, NHC, FMTS, University of Strasbourg, Strasbourg, France (Bourcier, Yaïci, Sanogo); Department of Ophthalmology, Brussels University and University Hospital of Brussels, Brussels, Belgium (Ní Dhubhghaill); Department of Biostatistics, Strasbourg University Hospital, Civil Hospital, FMTS, University of Strasbourg, Strasbourg, France (Lefebvre); King's College Hospital, London, United Kingdom (Aclimandos); Department of Ophthalmology, Center of Eye Diseases, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania (Asoklis); Department of Ophthalmology, Ankara University, School of Medicine, Ankara, Turkey (Atilla); Department of Ophthalmology, Dijon University Hospital, University of Dijon, Dijon, France (Creuzot-Garcher); Consultant Ophthalmologist, Clinical Lecturer, Royal College of Surgeons in Ireland, Dublin, Ireland (Curtin); Department of Ophthalmology, University Medical Centre Ljubljana, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia (Cvenkel); FS Exam Service Ltd., Dublin, Ireland (Flanagan, Strong); Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland (Kivelä); Department of Ophthalmology, Hospital Universitario y Politécnico La Fe, University of Valencia, Valencia, Spain (Martinez Costa); Department of Ophthalmology, LMU Munich, Munich, Germany (Priglinger); Department of Ophthalmology, West Lisbon Hospitals Center, Hospital Egas Moniz, Lisbon, Portugal (Prior Filipe); Department of Ophthalmology, Poznan University Hospital, Poznan University of Medical Sciences, Poznan, Poland (Stopa); Department of Ophthalmology, Cantonal Hospital Winterthur, University of Zurich, Zurich, Switzerland (Sturmer); Department of Ophthalmology, Antwerp University and University Hospital of Antwerp, Antwerp, Belgium (Tassignon); Department of Ophthalmology, University Medical Centre Sestre Milosrdnice, Zagreb, Croatia (Ivekovic); Manchester Royal Eye Hospital, Manchester, United Kingdom (Maino).
The impact of confined placental mosaicism on prenatal cell-free DNA screening: Insights from a monocentric study of 99 cases.
Placenta
July 2024
Department of Medical Genetics, Antwerp University and University Hospital, Drie Eikenstraat 655, 2650, Edegem, Belgium. Electronic address:
Introduction: Confined placental mosaicism (CPM) is thought to be one of the main sources of false-positive prenatal cell-free DNA (cfDNA) screening results, but extensive and systematic studies to prove this statement are limited. We evaluate the contribution of CPM to false-positive prenatal cfDNA screening results in the largest cohort published to date.
Method: We systematically offered postnatal analysis on placenta and umbilical cord to women who had a negative amniocentesis following a positive prenatal cfDNA screening result.
Cataract surgical training in Europe: European Board of Ophthalmology survey.
J Cataract Refract Surg
November 2023
From the Department of Ophthalmology, Antwerp University and University Hospital of Antwerp, Antwerp, Belgium (Ní Dhubhghaill, Tassignon); Department of Ophthalmology, Strasbourg University Hospital, NHC, FMTS, University of Strasbourg, Strasbourg, France (Sanogo, Bourcier); Department of Biostatistics, Strasbourg University Hospital, Civil Hospital, FMTS, University of Strasbourg, Strasbourg, France (Lefebvre); King's College Hospital, London, United Kingdom (Aclimandos); Department of Ophthalmology, Center of Eye Diseases, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania (Asoklis); Department of Ophthalmology, Ankara University, School of Medicine, Ankara, Turkey (Atilla); Department of Ophthalmology, Dijon University Hospital, University of Dijon, Dijon, France (Creuzot-Garcher); Consultant Ophthalmologist, Clinical Lecturer, Royal College of Surgeons in Ireland, Dublin, Ireland (Curtin); Department of Ophthalmology, University Medical Centre Ljubljana, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia (Cvenkel); EBO Secretariat Office, Agenda Communications and Conference Services, Ltd., Dublin, Ireland (Flanagan, Strong); Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland (Kivelä); Manchester Royal Eye Hospital, Manchester, United Kingdom (Maino); Department of Ophthalmology, Hospital Universitario y Politécnico La Fe, University of Valencia, Valencia, Spain (Martinez Costa); Department of Ophthalmology, LMU Munich, Germany (Priglinger); Department of Ophthalmology, West Lisbon Hospitals Center, Hospital Egas Moniz, Portugal (Prior Filipe); Department of Ophthalmology, Poznan University Hospital, Poznan University of Medical Sciences, Poland (Stopa); Department of Ophthalmology, Cantonal Hospital Winterthur, University of Zurich, Switzerland (Sturmer); Department of Ophthalmology, University Medical Centre Sestre Milosrdnice, Zagreb, Croatia (Ivekovic).
Purpose: To survey recently graduated European ophthalmologists concerning cataract surgery (CS) training opportunities.
Setting: Countries affiliated to the European Board of Ophthalmology (EBO).
Design: Cross-sectional study of anonymous survey results.
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial.
Lancet Oncol
April 2022
Leicester Cancer Research Centre, University of Leicester and University Hospitals of Leicester NHS Trust, Leicester, UK. Electronic address:
Article Synopsis
- This study looked at a new treatment called anetumab ravtansine for patients with a serious type of lung cancer called malignant pleural mesothelioma who didn't get better from previous treatments.
- Researchers wanted to see if this new drug worked better than an existing one called vinorelbine.
- They tested 248 patients in a fair way, where some got anetumab ravtansine and others got vinorelbine, to find out how long they could survive without the cancer getting worse.
Anti-Interleukin-5 Therapy Is Associated with Attenuated Lung Function Decline in Severe Eosinophilic Asthma Patients From the Belgian Severe Asthma Registry.
J Allergy Clin Immunol Pract
February 2022
Department of Respiratory Medicine, CHU Sart-Tilman, I(3)GIGA Research Group, University of Liège, Liège, Belgium.
Background: Asthmatics have accelerated lung function decline over time compared with healthy individuals.
Objective: To evaluate risk factors for accelerated lung function decline.
Methods: In a longitudinal analysis on severe asthmatics enrolled in the Belgian Severe Asthma Registry with at least 2 visits a minimum of 12 months apart, we compared characteristics of patients with and without decline (loss of post-bronchodilation forced expiratory volume in 1 s [FEV] (% predicted)/y greater than zero) over time.
This collaborative statement from the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia Pacific Heart Rhythm Society describes the current status of mobile health ("mHealth") technologies in arrhythmia management. The range of digital medical tools and heart rhythm disorders that they may be applied to and clinical decisions that may be enabled are discussed. The facilitation of comorbidity and lifestyle management (increasingly recognized to play a role in heart rhythm disorders) and patient self-management are novel aspects of mHealth.
View Article and Find Full Text PDFAthletes with valvular heart disease and competitive sports: a position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology.
Eur J Prev Cardiol
December 2021
Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Bad Oeynhausen, Germany.
This article provides an overview of the recommendations from the Sports Cardiology section of the European Association of Preventive Cardiology on sports participation in individuals with valvular heart disease (VHD). The aim of these recommendations is to encourage regular physical activity including sports participation, with reasonable precaution to ensure a high level of safety for all affected individuals. Valvular heart disease is usually an age-related degenerative process, predominantly affecting individuals in their fifth decade and onwards.
View Article and Find Full Text PDFThe European TeleCheck-AF project on remote app-based management of atrial fibrillation during the COVID-19 pandemic: centre and patient experiences.
Europace
July 2021
Department of Cardiology, Maastricht University Medical Centre, Cardiovascular Research Institute Maastricht, 6202 AZ Maastricht, The Netherlands.
Aims: TeleCheck-AF is a multicentre international project initiated to maintain care delivery for patients with atrial fibrillation (AF) during COVID-19 through teleconsultations supported by an on-demand photoplethysmography-based heart rate and rhythm monitoring app (FibriCheck®). We describe the characteristics, inclusion rates, and experiences from participating centres according the TeleCheck-AF infrastructure as well as characteristics and experiences from recruited patients.
Methods And Results: Three surveys exploring centre characteristics (n = 25), centre experiences (n = 23), and patient experiences (n = 826) were completed.
2021 ISHNE/HRS/EHRA/APHRS Expert Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia-Pacific Heart Rhythm Society.
Circ Arrhythm Electrophysiol
February 2021
Karolinska University Hospital, Stockholm, Sweden (E.S.).
This collaborative statement from the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia-Pacific Heart Rhythm Society describes the current status of mobile health technologies in arrhythmia management. The range of digital medical tools and heart rhythm disorders that they may be applied to and clinical decisions that may be enabled are discussed. The facilitation of comorbidity and lifestyle management (increasingly recognized to play a role in heart rhythm disorders) and patient self-management are novel aspects of mobile health.
View Article and Find Full Text PDF2021 ISHNE/ HRS/ EHRA/ APHRS collaborative statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia Pacific Heart Rhythm Society.
Ann Noninvasive Electrocardiol
March 2021
Karolinska University Hospital, Stockholm, Sweden.
This collaborative statement from the International Society for Holter and Noninvasive Electrocardiology/ Heart Rhythm Society/ European Heart Rhythm Association/ Asia Pacific Heart Rhythm Society describes the current status of mobile health ("mHealth") technologies in arrhythmia management. The range of digital medical tools and heart rhythm disorders that they may be applied to and clinical decisions that may be enabled are discussed. The facilitation of comorbidity and lifestyle management (increasingly recognized to play a role in heart rhythm disorders) and patient self-management are novel aspects of mHealth.
View Article and Find Full Text PDF2021 ISHNE / HRS / EHRA / APHRS Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology / Heart Rhythm Society / European Heart Rhythm Association / Asia Pacific Heart Rhythm Society.
Eur Heart J Digit Health
March 2021
Karolinska University Hospital, Stockholm, Sweden.
This collaborative statement from the International Society for Holter and Noninvasive Electrocardiology / Heart Rhythm Society / European Heart Rhythm Association / Asia Pacific Heart Rhythm Society describes the current status of mobile health ("mHealth") technologies in arrhythmia management. The range of digital medical tools and heart rhythm disorders that they may be applied to and clinical decisions that may be enabled are discussed. The facilitation of comorbidity and lifestyle management (increasingly recognized to play a role in heart rhythm disorders) and patient self-management are novel aspects of mHealth.
View Article and Find Full Text PDF2021 ISHNE/HRS/EHRA/APHRS Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia Pacific Heart Rhythm Society.
Cardiovasc Digit Health J
February 2021
Karolinska University Hospital, Stockholm, Sweden.
This collaborative statement from the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia Pacific Heart Rhythm Society describes the current status of mobile health ("mHealth") technologies in arrhythmia management. The range of digital medical tools and heart rhythm disorders that they may be applied to and clinical decisions that may be enabled are discussed. The facilitation of comorbidity and lifestyle management (increasingly recognized to play a role in heart rhythm disorders) and patient self-management are novel aspects of mHealth.
View Article and Find Full Text PDFDifferences in Thromboembolic Complications Between Paroxysmal and Persistent Atrial Fibrillation Patients Following Electrical Cardioversion (From the ENSURE-AF Study).
Am J Cardiol
September 2020
Arrhythmia and Robotic Electrophysiology Unit, Hospital Universitario La Paz, Universidad Europea, Madrid, Spain.
It is unclear if patients with paroxysmal atrial fibrillation (AF) and persistent AF have different outcomes following electrical cardioversion (ECV). ENSURE-AF-a multicenter, prospective, randomized, open-label, blinded-endpoint evaluation trial-compared once-daily edoxaban 60 mg with enoxaparin-warfarin in 2,199 subjects undergoing ECV of nonvalvular AF (NCT02072434). Patients received ≥3 weeks of proper anticoagulation or transesophageal echocardiogram before ECV paroxysmal AF was defined as AF with spontaneous conversion of duration of <7 days; persistent AF was defined as AF lasting ≥7 days without spontaneous conversion.
View Article and Find Full Text PDFHRS/EHRA/APHRS/LAHRS/ACC/AHA Worldwide Practice Update for Telehealth and Arrhythmia Monitoring During and After a Pandemic.
Circ Arrhythm Electrophysiol
July 2020
Oregon Health & Science University, Portland, OR (E.C.S.).
Effect of concomitant antiplatelet agents on clinical outcomes in the edoxaban vs warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomized trial.
Clin Res Cardiol
November 2020
Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart and Chest Hospital, Liverpool, UK.
Aims: In ENSURE-AF (NCT02072434), the oral Factor Xa inhibitor edoxaban showed similar efficacy and safety vs enoxaparin-warfarin in patients undergoing electrical cardioversion of nonvalvular atrial fibrillation (AF). This ancillary analysis compares primary efficacy and safety end points for patients receiving vs not receiving concomitant antiplatelet therapy (APT) in ENSURE-AF.
Methods: The primary efficacy end point was a composite of stroke, systemic embolic events, myocardial infarction, and cardiovascular death during 28 days on study drug after cardioversion plus 30 days of follow-up.
Determinants of left atrium thrombi in scheduled cardioversion: an ENSURE-AF study analysis.
Europace
November 2019
St. Vincenz-Hospital, Paderborn, Am Busdorf 2, Paderborn, Nordrhein-Westfalen, Germany.
Aims: ENSURE-AF (NCT02072434) was the largest prospective randomized clinical trial of anticoagulation for cardioversion in atrial fibrillation (AF), which also provides the largest prospective dataset for transoesophageal echocardiography (TOE) prior to cardioversion. This ancillary analysis investigated determinants of TOE-detected left atrium thrombi (LAT) in patients scheduled for electrical cardioversion (ECV).
Methods And Results: The ENSURE-AF multicentre PROBE evaluation trial compared edoxaban 60 mg once daily (QD) with enoxaparin/warfarin in 2199 subjects undergoing ECV of non-valvular AF.
Spontaneous conversion in patients with non-valvular atrial fibrillation planned for electrical cardioversion: A subanalysis of the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion Of Atrial Fibrillation (ENSURE-AF) trial.
Am Heart J
March 2019
Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.
Competitive athletes with implantable cardioverter-defibrillators-How to program? Data from the Implantable Cardioverter-Defibrillator Sports Registry.
Heart Rhythm
April 2019
Yale University Medical Center, New Haven, Connecticut.
Background: Athletes with an implantable cardioverter-defibrillator (ICD) may require unique optimal device-based tachycardia programming.
Objective: The purpose of this study was to assess the association of tachycardia programming characteristics of ICDs with occurrence of shocks, transient loss-of-consciousness, and death among athletes.
Methods: A subanalysis of a prospective, observational, international registry of 440 athletes with ICDs followed for a median of 44 months was performed.